Syndax Pharmaceuticals Inc (SNDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has a cash flow conversion efficiency ratio of -1.210x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.34 Million) by net assets ($41.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Syndax Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Syndax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SNDX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Syndax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FLEX LNG Ltd
NYSE:FLNG
|
0.040x |
|
Bank of Chongqing Co Ltd
F:CQN
|
-0.075x |
|
PowerTECH Co. Ltd. A
SHE:301369
|
N/A |
|
Parex Resources Inc
TO:PXT
|
0.012x |
|
Happy Forgings Limited
NSE:HAPPYFORGE
|
0.018x |
|
MicroPort Endovascular MedTech Ltd
SHG:688016
|
0.011x |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
-0.193x |
|
JBM Auto Limited
NSE:JBMA
|
-0.206x |
Annual Cash Flow Conversion Efficiency for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Syndax Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Syndax Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.63 Million | $-322.98 Million | -4.997x | -423.77% |
| 2024-12-31 | $288.12 Million | $-274.90 Million | -0.954x | -229.24% |
| 2023-12-31 | $554.20 Million | $-160.60 Million | -0.290x | -1.34% |
| 2022-12-31 | $467.45 Million | $-133.68 Million | -0.286x | -500.88% |
| 2021-12-31 | $408.37 Million | $29.13 Million | 0.071x | +125.25% |
| 2020-12-31 | $252.19 Million | $-71.26 Million | -0.283x | +82.36% |
| 2019-12-31 | $31.60 Million | $-50.61 Million | -1.602x | -23.98% |
| 2018-12-31 | $53.05 Million | $-68.53 Million | -1.292x | -184.50% |
| 2017-12-31 | $104.32 Million | $-47.37 Million | -0.454x | -8.68% |
| 2016-12-31 | $84.14 Million | $-35.16 Million | -0.418x | -1047.83% |
| 2015-12-31 | $66.70 Million | $-2.43 Million | -0.036x | -101.45% |
| 2014-12-31 | $-5.72 Million | $-14.39 Million | 2.518x | +508.99% |
| 2013-12-31 | $11.85 Million | $-7.29 Million | -0.616x | -294.22% |
| 2012-12-31 | $-29.29 Million | $-9.28 Million | 0.317x | -39.73% |
| 2011-12-31 | $-19.05 Million | $-10.02 Million | 0.526x | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more